Estimation of Skeletal Plutonium Levels Based on DTPA-induced Radionuclide Excretion in Feces

Mh, Bhattacharyya; Ra, Guilmette; Dp, Peterson; Fc, Chao; Lindinbaum, A

doi:10.1097/00004032-197806000-00003

Cited by 6 publications

(5 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…В многочисленных экспериментальных исследованиях установлено, что при комплексообразовании Ca-ДТПА в биологических средах конкурирует с эндогенными лигандами, такими как трансферрин и органические соли (карбонаты, цитраты), связывание ДТПА и плутония происходит в крови, экстрацеллюлярных жидкостях и в печени [26,27,28,29]. Несмотря на то, что в ряде экспериментальных исследований и наблюдений показана неэффективность удаления плутония и америция из костного объема [27,29], некоторые исследователи отмечают удаление актинидов из скелета, не объясняя механизмов процесса: происходит ли уменьшение активности в скелете за счет предотвращения его отложения в костной ткани или непосредственно за счет выведения актинидов из костного объема [12,30].…”

Section: результаты и обсуждениеunclassified

Assessing the applicability of a special model of plutonium behavior in presence of chelates in cases of wound intake of industrial compounds of plutonium in the FSUE Mayak PA workers

Sokolova,

Efimov,

Dzhunushaliev

2024

Radiac. gig. (2008)

View full text Add to dashboard Cite

In cases of intake of higher levels of plutonium, a chelate diethylenetriaminepentaacetic acid is used to enhance the elimination and reduce deposition rate in the organs of major deposit in the form of calcium compound Ca-DTPA (pentacinum). To interpret the results of the nuclide measurements in excreta while estimating the doses of internal exposure to plutonium, the biokinetic and dosimetry models recommended by ICRP are applied; and in case of the actinide intake through damaged skin it is recommended to use the models of NCRP of the USA. Since the application of chelates significantly changes the picture of plutonium urinary excretion, special models of complex Pu-DTPA behavior are developed to describe the plutonium biokinetics in presence of chelates. The purpose of this work is to assess the suitability of a special model of plutonium behavior in presence of chelates elaborated by K. Konzen to describe the plutonium biokinetics in the body by the cases of wound intake of industrial plutonium compounds in the FSUE Mayak PA workers. This study used the measurements of plutonium activity in daily amount of urine for three cases with the actinide intake through damaged skin and Ca-DTPA treatment, the duration of pentacinum application and observation periods for workers depending on the levels of intake. For each case, the most likely type of an entered compound was selected using Akaike information criterion, then the daily urinary activity of plutonium was calculated by the model (estimated value) on the same days when it was determined actually (actual values). The analysis of the compliance of calculated data with actual data was conducted using the statistic tests of Foster-Stewart,Breusch-Godfrey, Mann-Whitney, Shapiro-Wilk, and the determination coefficient. It was found that for all cases considered, the adjusted determination coefficient and Foster-Stewart test indicated the compliance of actual data with calculated ones. The statistical analysis of the compliance of calculated data with actual measurements of plutonium urinary activity showed that the special model of plutonium behavior proposed by K. Konzen was able to predict the urinary activity of plutonium during both the radionuclide decorporation measures and the period of pentacinum aftereffect.

show abstract

Section: результаты и обсуждениеunclassified

Assessing the applicability of a special model of plutonium behavior in presence of chelates in cases of wound intake of industrial compounds of plutonium in the FSUE Mayak PA workers

Sokolova,

Efimov,

Dzhunushaliev

2024

Radiac. gig. (2008)

View full text Add to dashboard Cite

show abstract

“…The initial blood compartment uptake indicates that the first day is important with respect to DTPA effectiveness. Chelation treatment is normally not recommended for an insoluble (Type S) intake, where a lung lavage may be advised for significant intakes (Bhattacharyya et al 1978a;USDOE 2008).…”

Section: Lung Retentionmentioning

confidence: 99%

Development of the Plutonium-DTPA Biokinetic Model

Konzen

Brey²

2015

Health Physics

View full text Add to dashboard Cite

Estimating radionuclide intakes from bioassays following chelation treatment presents a challenge to the dosimetrist due to the observed excretion enhancement of the particular radionuclide of concern where no standard biokinetic model exists. This document provides a Pu-DTPA biokinetic model that may be used for making such determination for plutonium intakes. The Pu-DTPA biokinetic model is intended to supplement the standard recommended biokinetic models. The model was used to evaluate several chelation strategies that resulted in providing recommendations for effective treatment. These recommendations supported early treatment for soluble particle inhalations and an initial 3-day series of DTPA treatments for wounds. Several late chelation strategies were also compared where reduced treatment frequencies proved to be as effective as multiple treatments. The Pu-DTPA biokinetic model can be used to assist in estimating initial intakes of transuranic radionuclides and for studying the effects of different treatment strategies.

show abstract

“…The DCF 21 or dose conversion factor is the effective dose coefficient for inhalation [e inh (50) When discussing the MDD for a radiobioassay program it is convenient to have a single value. This provides correlation between the MDD for a particular analysis at a specific time interval, (MDD(t)), to the performance objective.…”

Section: Minimum Detectable Dose For Routine Radiobioassaymentioning

confidence: 99%

“…Most of this increase is assumed to come from the chelation of free plutonium in the blood; that is, the increase in urinary excretion reflects unincorporated plutonium. Excretion of plutonium in the bile also increases but reflects the removal of plutonium that was incorporated in the liver 50 . As a rough approximation for an acute injection intake of plutonium, it is assumed that the feces excretion rate will be ~1/3 of the urinary excretion rate following chelation therapy.…”

Section: Effect Of Chelation On Feces Excretionmentioning

confidence: 99%